ArticleNature communications2025
Chiral substrate-induced chiral covalent organic framework membranes for enantioselective separation of macromolecular drug.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Chalcogen-bonding-mediated chiral recognition and enantioenrichment of organoselenocyanates.Chemical science · 2026Article
- Chiral (Stereoselective) Drugs, Asymmetric Synthesis, and Racemic Resolution Methods.Chirality · 2026Review
- Contact Electrification-Based Enantioselective Recognition of Chiral Amino Acids through Stereospecific Interfacial Electron Transfer.Journal of the American Chemical Society · 2026Article
- Thiazole-conjugated covalent organic framework membranes enable ultraselective molecular desalination under strongly acidic conditions.Nature communications · 2026Article
- A UniversalACS measurement science au · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Chiral drugs are essential in modern medicine, but separating their enantiomers is challenging due to their similar physicochemical properties. However, traditional methods are often costly and inefficient. Here we show that chiral covalent organic framework (CCOF-300) membranes, induced by chiral dopants (L-( + )-/D-(-)-tartaric acid), can achieve high enantioselectivity in separating chiral drugs. Specifically, CCOF-300 membrane achieved 100% enantiomeric excess in separating racemic N-Fmoc-N'-[1-(4,4-Dimethyl-2,6-dioxocyclohexylidene)ethyl]-lysine (Fmoc-Lys(Dde)-OH). We found that size matching and differences in diffusion rates between enantiomers are key factors in chiral separation. Additionally, there were no significant differences in the binding energy between ibuprofen (IBU), Fmoc-Lys(Dde)-OH, and CCOF-300, indicating that binding energy is not the dominant factor in chiral separation. This study proposes a cost-effective and scalable method for chiral drug separation, highlighting the potential of chiral induction strategy in improving chiral separation technology in the pharmaceutical industry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.